Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isavuconazonium Sulfate

FDA-approved product (capsule, oral), marketed as Cresemba.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Isavuconazonium Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Mucormycosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Isavuconazonium Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isavuconazonium Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

    NCT07780565 · start 2027-01-01

    Registered record
    Registry ID
    NCT07780565
    Conditions
    Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome
    Interventions
    Monzosertib; Posaconazole; Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2031-08-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML); Myelodysplastic Syndrome
    InterventionMonzosertib; Posaconazole; Isavuconazole
    PhasePhase 1
    Registry statusNot yet recruiting

  • Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population

    NCT07496008 · start 2026-03-25

    Registered record
    Registry ID
    NCT07496008
    Conditions
    Isavuconazole; Invasion Pulmonary Mycosis
    Interventions
    Liquid chromatography-tandem mass spectrometry
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-25
    Completion
    2029-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIsavuconazole; Invasion Pulmonary Mycosis
    InterventionLiquid chromatography-tandem mass spectrometry
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Imetelstat Combinations in Relapsed AML

    NCT07320235 · start 2026-01-02

    Registered record
    Registry ID
    NCT07320235
    Conditions
    Relapsed Acute Myeloid Leukemia
    Interventions
    Imetelstat; Azacitidine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-01-02
    Completion
    2035-06-15
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Acute Myeloid Leukemia
    InterventionImetelstat; Azacitidine; Venetoclax
    PhasePhase 1
    Registry statusRecruiting

  • Isavuconazole in Critically Ill Patients: Efficacy and Safety

    NCT07080359 · start 2025-08-01

    Registered record
    Registry ID
    NCT07080359
    Conditions
    Fungal Infection; Aspergillosis; Mucormycosis
    Interventions
    Isavuconazole treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-08-01
    Completion
    2030-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection; Aspergillosis; Mucormycosis
    InterventionIsavuconazole treatment
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases

    NCT07135778 · start 2025-05-19

    Registered record
    Registry ID
    NCT07135778
    Conditions
    Invasive Fungal Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-05-19
    Completion
    2026-12-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study

    NCT07191756 · start 2025-05-15

    Registered record
    Registry ID
    NCT07191756
    Conditions
    Mucormycosis
    Interventions
    Amphotericin B; Isavuconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-05-15
    Completion
    2025-09-25
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis
    InterventionAmphotericin B; Isavuconazole
    PhaseNot recorded
    Registry statusActive not recruiting

  • Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

    NCT07185503 · start 2025-03-25

    Registered record
    Registry ID
    NCT07185503
    Conditions
    Mucormycosis in Hematologic Malignancies
    Interventions
    liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2027-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis in Hematologic Malignancies
    Interventionliposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
    PhaseNot recorded
    Registry statusRecruiting

  • Antifungal Drugs in Pulmonary Mucormycosis

    NCT06756191 · start 2025-01-10

    Registered record
    Registry ID
    NCT06756191
    Conditions
    Pulmonary Mucormycosis
    Interventions
    Combination therapy group; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-01-10
    Completion
    2026-12-31
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Mucormycosis
    InterventionCombination therapy group; Liposomal Amphotericin B
    PhasePhase 4
    Registry statusNot yet recruiting

  • Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children

    NCT06440915 · start 2024-06-06

    Registered record
    Registry ID
    NCT06440915
    Conditions
    Aspergillosis Invasive; Mucormycosis
    Interventions
    Theraputic drug monitoring; Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-06-06
    Completion
    2026-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis Invasive; Mucormycosis
    InterventionTheraputic drug monitoring; Isavuconazole
    PhaseNot applicable
    Registry statusRecruiting

  • Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

    NCT05630976 · start 2023-02-07

    Registered record
    Registry ID
    NCT05630976
    Conditions
    Invasive Fungal Disease
    Interventions
    Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-07
    Completion
    2025-04-11
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Disease
    InterventionIsavuconazole
    PhasePhase 4
    Registry statusCompleted

  • Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

    NCT05468372 · start 2022-07-01

    Registered record
    Registry ID
    NCT05468372
    Conditions
    Mucormycosis; Pulmonary (Etiology)
    Interventions
    Posaconazole 600 mg followed by posaconazole 300 mg once daily; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-01
    Completion
    2026-02-01
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis; Pulmonary (Etiology)
    InterventionPosaconazole 600 mg followed by posaconazole 300 mg once daily; Liposomal Amphotericin B
    PhasePhase 2
    Registry statusCompleted

  • Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.

    NCT05426499 · start 2021-10-01

    Registered record
    Registry ID
    NCT05426499
    Conditions
    Population Modeling of Anti-infective Drugs
    Interventions
    Patients requiring cefotaxime treatment; Patients requiring meropenem treatment; Patients requiring fluconazole treatment; Patients requiring isavuconazole treatment; Patients requiring anidulafungin treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2025-09-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPopulation Modeling of Anti-infective Drugs
    InterventionPatients requiring cefotaxime treatment; Patients requiring meropenem treatment; Patients requiring fluconazole treatment; Patients requiring isavuconazole treatment +1 more
    PhaseNot recorded
    Registry statusUnknown

  • European Study of Cerebral Aspergillosis Treated With Isavuconazole

    NCT04486885 · start 2021-08-01

    Registered record
    Registry ID
    NCT04486885
    Conditions
    Cerebral Aspergillosis; Invasive Aspergillosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-08-01
    Completion
    2023-03-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Aspergillosis; Invasive Aspergillosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

    NCT04707703 · start 2021-03-16

    Registered record
    Registry ID
    NCT04707703
    Conditions
    Severe Acute Respiratory Syndrome Coronavirus 2; Aspergillosis Invasive
    Interventions
    Isavuconazonium Injection [Cresemba]; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-03-16
    Completion
    2021-10-25
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Acute Respiratory Syndrome Coronavirus 2; Aspergillosis Invasive
    InterventionIsavuconazonium Injection [Cresemba]; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.

    NCT04550936 · start 2021-03-10

    Registered record
    Registry ID
    NCT04550936
    Conditions
    Invasive Aspergillosis; Mucormycosis
    Interventions
    Isavuconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-10
    Completion
    2023-12-23
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis; Mucormycosis
    InterventionIsavuconazole
    PhaseNot recorded
    Registry statusCompleted